TY - JOUR
T1 - Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation
AU - Nakamura, Kenichi
AU - Ozawa, Hitoshi
AU - Shibata, Taro
AU - Ushirozawa, Nobuko
AU - Hata, Tomomi
AU - Okita, Natsuko
AU - Fuse, Nozomu
AU - Sato, Norihiro
AU - Ikeda, Koji
AU - Hanaoka, Hideki
AU - Maruyama, Tatsuya
AU - Wada, Michihiko
AU - Shimizu, Shinobu
AU - Kasai, Hiroi
AU - Yamamoto, Yoichi
AU - Sakurai, Jun
AU - Todaka, Koji
AU - Tashiro, Shimon
AU - Yamamoto, Haruko
N1 - Funding Information:
This work was conducted under a Science Research Grant funded by the Ministry of Health, Labour and Welfare, Japan (20CA2011).
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/3
Y1 - 2022/3
N2 - Background: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is undertaking a major revision of ICH E6 Good Clinical Practice (GCP) decided to involve external stakeholders in ICH-GCP renovation. Activities such as surveys and public conferences have taken place in the United States, European Union, and Japan. For stakeholder engagement in Japan, a designated research group conducted a survey of academic stakeholders. Methods: A total of 105 academic stakeholders from 18 institutions responded to the survey. The research group developed recommendations reflecting the survey results and the opinions from patients and the public. Results: The survey showed the top four principles needing renovation were (i) informed consent (Chapter 2.9, 12.4% of respondents believed it needed renovation), (ii) systems for quality assurance (Chapter 2.13, 9.5%), (iii) information on an investigational product (Chapter 2.4, 5.7%), and (iv) procedures on clinical trial information (Chapter 2.10, 5.7%). The top three sections identified as needing renovation were: (i) informed consent (Chapter 4.8, 27.6%), (ii) monitoring (Chapter 5.18, 22.9%), and (iii) composition, functions, and operations of the ethics committee (Chapter 3.2, 14.3%). Recommendations included clarification of ICH-GCP’s scope, proportionality in various aspects of clinical trials, diversity and liquidity of ethics committee members, modernization of informed consent procedures, variations in monitoring, and regulatory grade when using real-world data. Conclusion: The recommendations from Japanese investigators and patients have been submitted to the ICH E6 Expert Working Group, which will strengthen the robustness of the GCP renovation.
AB - Background: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is undertaking a major revision of ICH E6 Good Clinical Practice (GCP) decided to involve external stakeholders in ICH-GCP renovation. Activities such as surveys and public conferences have taken place in the United States, European Union, and Japan. For stakeholder engagement in Japan, a designated research group conducted a survey of academic stakeholders. Methods: A total of 105 academic stakeholders from 18 institutions responded to the survey. The research group developed recommendations reflecting the survey results and the opinions from patients and the public. Results: The survey showed the top four principles needing renovation were (i) informed consent (Chapter 2.9, 12.4% of respondents believed it needed renovation), (ii) systems for quality assurance (Chapter 2.13, 9.5%), (iii) information on an investigational product (Chapter 2.4, 5.7%), and (iv) procedures on clinical trial information (Chapter 2.10, 5.7%). The top three sections identified as needing renovation were: (i) informed consent (Chapter 4.8, 27.6%), (ii) monitoring (Chapter 5.18, 22.9%), and (iii) composition, functions, and operations of the ethics committee (Chapter 3.2, 14.3%). Recommendations included clarification of ICH-GCP’s scope, proportionality in various aspects of clinical trials, diversity and liquidity of ethics committee members, modernization of informed consent procedures, variations in monitoring, and regulatory grade when using real-world data. Conclusion: The recommendations from Japanese investigators and patients have been submitted to the ICH E6 Expert Working Group, which will strengthen the robustness of the GCP renovation.
KW - Clinical trial regulation
KW - Good Clinical Practice
KW - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
KW - Real-world data
KW - Remote monitoring
UR - http://www.scopus.com/inward/record.url?scp=85119186052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119186052&partnerID=8YFLogxK
U2 - 10.1007/s43441-021-00350-4
DO - 10.1007/s43441-021-00350-4
M3 - Article
C2 - 34787814
AN - SCOPUS:85119186052
SN - 2168-4790
VL - 56
SP - 220
EP - 229
JO - Therapeutic Innovation and Regulatory Science
JF - Therapeutic Innovation and Regulatory Science
IS - 2
ER -